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3 involved in the pathogenesis of arsenic-mediated cutaneous inflammation which may also be related to enhanced cancer risk in arsenic exposed cohorts.
Introduction
Exposure to arsenic, a highly toxic metalloid, occurs through occupational and environmental pollution. More recently, contamination of groundwater due to interaction of rocks and minerals containing soluble arsenic caused widespread chronic human arsenic exposure in geographical areas including Bangladesh, Taiwan, Mexico, Mongolia, Argentina, India, Chile, and in some parts of the USA.
Approximately 100 million people are exposed to toxic concentrations of arsenic worldwide (1, 2) , which is associated with enhanced morbidity and mortality (3) .
Enhanced risk for various cancers including bladder, kidney, lung and skin has been associated with arsenic exposure in a dose-dependent manner (4) . However, the mechanism by which arsenic causes toxic and carcinogenic manifestations remains largely unknown.
Endoplasmic reticulum (ER) is the site of biosynthesis, folding, assembly and maturation of many secretary and membrane-bound proteins. Increased demand for folded proteins disturbs homeostasis of ER and may result in accumulation of unfolded or misfolded proteins leading to the condition known as ER stress.
Unfolded protein response (UPR) signaling restores the protein folding capacity of ER and provides a balance between protein-folding overload and impaired ER capacity. This is done in a translational-and transcriptional-dependent manner by engaging three ER membrane resident proteins: PERK, IRE1 and ATF6 (5) . In addition to restoring protein folding capacity of ER, UPR is involved in obesity, diabetes, atherosclerosis, neurodegenerative diseases, inflammation and cancers (6, 7) . Some of these conditions have also been reported in arsenic-exposed populations (1, 3, 4) .
Arsenic induces precancerous lesions, melanosis and keratosis some of which progress to basal cell (BCC) and squamous cell carcinoma (SCC) (8, 9) . We hypothesized that one mechanism by which these early changes occur in arsenic exposed populations may involve activation of UPR signaling pathways. UPR signaling may mediate cutaneous inflammation and enhance cancer risk (6, 7, 10) .
In this study, we employed SKH-1 hairless mice as a murine model to study the pathogenesis of arsenic-induced inflammation. Our data showed that arsenic induced UPR signaling by activating three classic pathways conserved throughout the eukaryotic system, and concomitantly activated pro-inflammatory p38 MAPK and cytokine/chemokine signaling pathways. Interestingly, arsenic induced these signaling pathways in a reactive oxygen species (ROS)-dependent manner and antioxidant N-acetyl cysteine (NAC) treatment attenuated some of these effects.
These data provide a novel mechanism by which toxic and carcinogenic effects of arsenic are mediated.
Materials and Methods

Reagents
Primary antibodies as listed in supplemental Table 1 
Animal model
In the first experiment, twenty-five age-matched SKH-1 hairless mice (5 mice/group) were fed ad libitum respectively drinking water containing arsenic at 0ppm, 50ppm, 100ppm and 200ppm concentrations for a period of 1 month. Then all of these animals were killed, their skin excised and processed for histology/immunohistochemistry/immunofluorescence studies or western blot/PCR analysis. The dose selection in the current experiments is based on ten year consumption of arsenic by a human population in geographical areas with high arsenic levels in drinking water (150.1-864.0µg/L) considering an average consumption of 1.5L water/person/day. This population manifests various cutaneous lesions (3) . We also studied the effects of arsenic at a dose level of 300 ppm. However, this dose was cytotoxic and did not follow the dose response relationship exhibited by the majority of other doses, except that related to inflammatory response assessment. termination of the experiment. At the termination of the experiment, skin samples were collected for analysis as described above.
Western blot analysis
Skin tissues were homogenized in an ice-cold lysis buffer (50mM Tris pH 7.5, 1% Triton X-100, 0.25% NaF, 10mM β-glycerolphosphate, 2mM EDTA, 5mM
Sodium pyrophosphate, 1mM Na3VO4, 10mM DTT and protease inhibitor). Clear lysate was prepared by centrifugation at 10,000 g for 10 minutes. Extracts were aliquoted in small volumes and stored at -80ºC before use. Aliquots of total tissue homogenates were mixed with 4 X loading buffer, boiled for 5 minutes and subjected to SDS-PAGE. Proteins were electrophoretically transferred to PVDF membranes and then nonspecific sites were blocked with 5% (W/V) nonfat-dry milk in TBST (25mM Tris-HCl, pH 7.5; 150mM NaCl; 0.05% Tween-20) for 1h at RT followed by probing with primary antibody overnight at 4ºC or 1h at RT. The membranes were incubated for 1h with HRP-conjugated secondary antibody. The blots were developed with ECL according to the manufacture's instructions (Amersham, IL). In most cases 40µg protein was loaded. However, to detect phosphorylation of PERK, 100µg lysates were subjected to 6% SDS-PAGE to obtain a better resolution. The membranes were probed with anti-PERK antibody and developed by ECL as described above. At least three independent samples from each group were used for Western blot analysis. The integrated density of 
RT-PCR
Total RNA was isolated from skin according to manufacturer's protocol using TRIzol® Reagent (Catalog No. 15596-026) extraction kit (Invitrogen). RNA concentration and purity were determined by measuring OD260 and OD 260/280. 1μg RNA was used for reverse transcription using iScript cDNA synthesis kit (BioRad). Primers used in this study are described in Supplementary Table 2 .
PCR Array
PCR Array was performed using SABiosciences PCR Array System. First strand cDNA synthesis was performed using RT 
Statistical analysis
Statistical analysis was performed using Student's t test, p < 0.05 was considered to be statistically significant. Similarly, we observed that ATF6α p90 and ATF6α p50 were both significantly upregulated following arsenic treatment ( Figure 1A ). The two other important UPR signaling proteins GRP78 and GRP94 were also increased significantly ( Figure   1C ). We also recorded significant increase of CHOP and GRP78 in mRNA level (Figure1B). Immunofluorescent staining for CHOP, XBP-1, ATF6α and GRP78 in the skin showed that in control animals low levels of these proteins were localized in the basal layer of epidermis. However, their increased expression and nuclear localization ( Figure 1D ) both in basal and suprabasal epidermis confirmed activation of these UPR pathways following arsenic exposure.
Results
Arsenic activates cutaneous UPR
Arsenic-induced ROS acts upstream of UPR signaling: Previously, we and others showed that arsenic induces ROS production in vitro in cells in culture ( an important role in UPR signaling during the pathogenesis of various cancers (7, 13) . Significantly enhanced epidermal fluorescent staining was observed in arsenic-treated animals compared to vehicle-treated controls (Figure 2A ). Arsenicenhanced fluorescent staining attenuated following pre-treatment of arsenic exposed animals with antioxidant NAC, confirming that arsenic also augments ROS production in the skin (Figure 2A ). To demonstrate that ROS production by arsenic is upstream of arsenic-mediated enhancement in UPR signaling, we tested whether NAC treatment can dampen UPR signaling. As shown in Figure 2B , arsenic-mediated enhancement of the expression of UPR marker proteins, p-eIF2α, XBP-1s and ATF6α was decreased significantly (p<0.02) in the NAC treatment group which correlated with the decrease in ROS production in the epidermis of these animals. Furthermore, the relative expression levels of UPR signaling readout proteins, GRP78 and GRP94 showed identical decrease ( Figure 2B ).
These data demonstrate that arsenic-induced UPR signaling in the skin of SKH-1 mice was regulated by ROS production.
Arsenic enhances cutaneous inflammation via UPR signaling:
Cutaneous inflammation is observed in arsenic exposed humans and is associated with enhanced keratosis and pitting of the palms and soles (8, 9, 14) . We therefore tested whether arsenic mediated similar inflammatory changes in murine skin. For this, we assessed inflammatory signaling pathways, MAP Kinase and cytokine/chemokine signaling, which were found to be associated with cutaneous inflammation (15, 16) . Arsenic treatment increased expression of p-p38, and p-MAPKAPK-2. Although the basal levels of MAPKAPK-2 were significantly augmented, p38 levels remained largely unaffected ( Figure 2C) . Similarly, we did not detect significant changes in the levels of total or p-ERK (data not shown). We also examined whether ROS production contributed to the induction of p38 MAP kinase signaling. The ability of NAC to significantly diminish the levels of arsenicinduced p-p38, p-MAPKAPK-2 and MAPKAPK-2 in this study ( Figure 2D ) suggests that ROS production triggered arsenic-mediated inflammation.
Furthermore, employing a mouse inflammatory cytokine/chemokine PCR array containing 84 genes, we detected gene expression signatures characterizing Th1, Th2 and Th17 microenvironment as described in Supplementary Tables 3 and 4. Arsenic upregulated 24 genes whereas it downregulated 20 genes and the remaining 43 genes were not significantly altered ( Figure 3A X-C motif chemokine 5) and Cxcl1 (encoding C-X-C motif chemokine 1), showed significant changes in their expression. However, at arsenic dose 300 ppm we also observed significant increase of 2 fold in the expression of Spp1 encoding secreted phosphoprotein 1, which is known to polarize immune response to Th1 type (19) .
Similarly, a significant decrease in the expression of Ccl22 encoding Chemokine (C-C motif) ligand 22 was observed at this dose. Concomitant with its effect on ROS production, UPR and MAP kinase signaling activation, NAC treatment also ameliorated cytokine/chemokine expression profile. Upon NAC treatment among 15 genes which were significantly upregulated, 12 genes including 3 Th1 markers (Il1b, Ccl4 and Tnf) were significantly reversed. However, out of the 14 downregulated genes (including 3 Th2 markers, Il20, Ccl1 and Il15; and 2 Th17 markers, Il15 and Cxcl5) only three (CX3cl1, Abcf1, Tollip1) showed a significant recovery (data not shown). Although we and others observed a number of biochemical changes in the skin of SKH-1 mice following arsenic exposure through drinking water, visually no pathobiological effects were observed in these animals.
Arsenic treatment by itself does not induce skin cancer or hyperkeratosis in any of the known murine models. The only murine model so far described for arsenicinduced cancer is the in utero transplacental treatment model (20) .
Discussion
Arsenic is a known human cutaneous toxicant and carcinogen (1, 2) . In this paper we describe a novel mechanism by which arsenic induces cutaneous inflammation ( Figure 4) . We demonstrated that arsenic activated all three known UPR signaling pathways, indicating that ER stress is one of the major underlying 
13 mechanisms of arsenic toxicity/carcinogenicity. These results are consistent with the current notion that ER stress is involved in the pathobiology of multiple disease conditions including inflammation and cancer (6, 7) . In the skin, UPR pathway is known to alter differentiation (21) which is consistent with the frequent appearance of hyperkeratosis in arsenic exposed humans. Skin cancer and other cutaneous manifestations are usually observed following a decade of arsenic exposure, particularly in geographical areas of high arsenic levels in water. We therefore utilized relatively higher arsenic levels in our animal experiments to unravel the molecular mechanisms associated with high arsenic. Our observations that arsenic activated UPR signaling which is linked to cutaneous inflammation may also partially explain the observed augmented skin cancer risk in exposed populations (10) .
The demonstration in this study that NAC blocked arsenic-mediated ROS production with a concomitant attenuation of UPR, MAP kinase and other cytokine/chemokine signaling pathways suggests that arsenic-mediated ROS production triggered these pathways, and that blocking ROS production in exposed populations may be beneficial in reducing inflammation and possibly cancer as predicted in Figure 4 . Our results confirmed other studies showing that NAC as well as other antioxidants protect against arsenic-associated cutaneous toxicity (22) . In this regard, the results from a recent NIH/NCI clinical trial in Bangladesh 
mechanisms invoke arsenic-mediated pathogenesis of skin diseases in murine models and in humans.
Although both ROS and UPR pathways regulate inflammatory response independently (6, 15) , it is not clear from our studies whether the observed cutaneous inflammatory response was attributable to crosstalk between the two pathways or to each pathway independently. The partial but significant recovery of MAP kinase signaling following NAC treatment coupled with identical cytokine/chemokine signaling gene profile suggests that UPR and/or other undefined ROS-independent factors regulate arsenic-mediated cutaneous inflammation. Defining these intricate relationships is beyond the scope of this report. However, it is known that under certain experimental settings MAPK signaling regulates both the expression of inflammation provoking and UPR signaling related proteins (23) . In summary, our data indicate that UPR signaling is involved in arsenic-mediated cutaneous pathobiology and that production of ROS plays a key role in triggering this response. 
